CVC co-director, Dr. Padma Kaul, was recently appointed the CIHR Sex and Gender Science Chair in Diabetes. Her research project, the REDISCOVER study, will provide new insights into the relationship of sex and diabetes on cardiovascular outcomes. In an interview with the University of Alberta’s Faculty of Medicine & Dentistry, Dr. Kaul discusses this research […]
We are pleased to share the 2019 CVC annual report. This year’s theme, A Decade of Discovery, celebrates the pathway forged by the CVC over the past ten years. Our staff and faculty have all made important contributions to this compendium. We hope you enjoy reading more about who we are and what we do […]
We are pleased to share with you the spring 2020 edition of the Canadian Cardiac Chronicle. Along with our current trial updates and feature publications, the following items are highlighted in this issue: A letter from CVC Co-Director Dr. Justin Ezekowitz reflecting upon adapting to the current challenging events, celebrating accomplishments, and continuing to remain creative […]
Dr. Kevin Bainey, Director of the CVC ECG Core Laboratory, was featured on multiple news outlets discussing key results from the recent publication Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice: Insights From the Vital Heart Response Registry. This publication was also coauthored by several other members of the […]
Congratulations to Drs. Ana Savu, Linn Moore and Padma Kaul, along with their fellow coauthors, on the publication of their article Elevated fasting vs post-load glucose levels and pregnancy outcomes in gestational diabetes: a population-based study in Diabetic Medicine. It is known that women with gestational diabetes mellitus (GDM) are at an increased risk of […]
On November 18th it was announced that the Phase 3 VICTORIA study evaluating the efficacy and safety of vericiguat, a soluble guanylate cyclase (sGC) stimulator being developed to treat patients with worsening chronic heart failure, has met the primary efficacy endpoint. Vericiguat reduced the risk of the composite endpoint of heart failure hospitalization or cardiovascular […]
The CVC has officially moved! Our new offices are located at the following address: 4-120 Katz Group Centre for Pharmacy and Health ResearchUniversity of AlbertaEdmonton, AB T6G 2E1 Visit our contact page to view our new building location on Google Maps.
On behalf of the Canadian VIGOUR Centre (CVC) and the Beyond 2018 (B2K18) educational program, we are pleased to share a Canadian Cardiovascular Society-accredited webinar series initiative that is being provided as an extension to the B2K18 symposium (held annually during the Canadian Cardiovascular Congress, most recently October 22, 2018). The 5th webinar in this […]
We are pleased to share the 2018 Canadian VIGOUR Centre (CVC) Annual Report. This year’s report highlights the results of our organization’s focus in 2018 and emphasizes our continuing commitment to enhancing human health through innovation and training the next generation of health researchers. Our staff and faculty have all contributed to this compendium and […]
